News
Public Health Vaccines announces initiation of first clinical trial evaluating its Marburg virus vaccine
March 21, 2024
CAMBRIDGE, MA – March 21, 2024 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA developing novel products against emerging infectious diseases, has started its Phase 1 clinical trial (NCT06265012) to evaluate the safety and immunogenicity of the company’s single-dose vaccine (PHV01) against Marburg virus—a hemorrhagic fever virus of the Filoviridae family that causes Marburg Virus Disease, a rare but severe hemorrhagic fever that affects people and non-human primates and has a case fatality rate of up to 88%. In addition to being a naturally occurring public health threat on the World Health Organization’s list of priority pathogens with potential to cause future outbreaks and pandemics, Marburg virus has been identified as a Category A Select Agent. Read More
Public Health Vaccines announces the initiation of the first clinical trial evaluating its Nipah virus vaccine
February 09, 2022
CAMBRIDGE, MA – February 09, 2022 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA developing novel products against emerging infectious diseases, today announced the start of its Phase 1 clinical trial to evaluate the safety and immunogenicity of the company’s single-dose vaccine (PHV02) against Nipah virus—a bat-borne virus that can spread to both humans and livestock causing serious illness, including encephalitis, pneumonia and death. Read More
Public Health Vaccines awarded first options under advanced development contract from BARDA to continue development of vaccine against Marburg virus
June 23, 2021
CAMBRIDGE, MA – June 23, 2021 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has been awarded the first two options under its Biomedical Advanced Research and Development Authority (BARDA) contract for the advanced development of its vaccine candidate designed to prevent Marburg virus infections. PHV is leveraging the proven recombinant vesicular stomatitis virus (rVSV) vector platform originally developed by the Public Health Agency of Canada. Read More
CEPI awards up to US$43.6 million to Public Health Vaccines, LLC. for development of a single-dose Nipah virus vaccine candidate
August 12, 2019
Oslo, Norway and Cambridge, MA, USA; August 12, 2019—The Coalition for Epidemic Preparedness Innovations (CEPI) and Public Health Vaccines, LLC. (PHV) have announced a partnering agreement worth up to US$ 43.6 million to advance the development and manufacture of a vaccine against the Nipah virus… Read More
Public Health Vaccines awarded advanced development contract from BARDA to develop vaccine against Marburg virus
March 5, 2019
CAMBRIDGE, MA – March 5, 2019 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has been awarded a contract for the advanced development of its vaccine candidate designed to prevent Marburg virus infections. PHV will leverage the proven recombinant vesicular stomatitis virus (rVSV) vector platform originally developed by the Public Health Agency of Canada (PHAC). Read More
Public Health Vaccines to develop vaccines against infectious disease threats, including Marburg virus and Sudan ebolavirus.
February 6, 2019
CAMBRIDGE, MA – February 6, 2019 – Public Health Vaccines, LLC (PHV), a biotechnology company out of Cambridge, MA, has entered into a license arrangement with the Public Health Agency of Canada (PHAC) to leverage the advanced recombinant vesicular stomatitis virus (rVSV) vector platform that PHAC discovered in 2005, to develop vaccines against Marburg virus and Sudan ebolavirus. Read More
